Experimental heart drug combo begins first human safety tests
NCT ID NCT07309042
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test the safety of combining an experimental drug called YN001 with the statin rosuvastatin in 24 healthy Chinese adults aged 18 to 55. Participants will receive YN001 by infusion and rosuvastatin tablets over several weeks. The main goal is to see if the combination is safe and tolerable, and how the drugs interact in the body. This study does not aim to treat disease, but to gather information for future trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YN001 (an experimental drug) and rosuvastatin (a statin)
- What this could lead to
- If successful, this could show that YN001 can be safely combined with statins, paving the way for future studies in people with heart or blood vessel disease.
- What could go wrong
- This is a very early, small trial in healthy volunteers, not patients. It only checks safety and drug levels, not whether the combination actually treats disease. Many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.